Moody Aldrich Partners LLC Purchases New Position in Insmed Incorporated (NASDAQ:INSM)

Moody Aldrich Partners LLC purchased a new stake in Insmed Incorporated (NASDAQ:INSM) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 35,478 shares of the biopharmaceutical company’s stock, valued at approximately $2,449,000.

Other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new stake in Insmed in the 2nd quarter worth approximately $810,000. Squarepoint Ops LLC acquired a new stake in Insmed in the 2nd quarter worth approximately $3,387,000. AQR Capital Management LLC lifted its holdings in Insmed by 59.7% in the 2nd quarter. AQR Capital Management LLC now owns 60,527 shares of the biopharmaceutical company’s stock worth $4,055,000 after purchasing an additional 22,616 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Insmed by 21.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 283,011 shares of the biopharmaceutical company’s stock worth $18,962,000 after purchasing an additional 50,330 shares during the last quarter. Finally, Creative Planning lifted its holdings in Insmed by 63.8% in the 2nd quarter. Creative Planning now owns 34,246 shares of the biopharmaceutical company’s stock worth $2,294,000 after purchasing an additional 13,342 shares during the last quarter.

Insmed Stock Up 1.1 %

Shares of NASDAQ INSM opened at $78.46 on Wednesday. The business has a fifty day simple moving average of $72.17 and a 200 day simple moving average of $72.93. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter last year, the business earned ($1.10) EPS. Insmed’s revenue for the quarter was up 18.1% on a year-over-year basis. As a group, equities research analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on INSM. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Truist Financial restated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. upped their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. Finally, Bank of America upped their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Insider Buying and Selling at Insmed

In other news, COO Roger Adsett sold 2,444 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.95, for a total transaction of $161,181.80. Following the sale, the chief operating officer now owns 147,666 shares in the company, valued at approximately $9,738,572.70. This represents a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now owns 102,766 shares in the company, valued at $6,773,307.06. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,740 shares of company stock worth $7,161,294 over the last three months. Company insiders own 4.60% of the company’s stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.